Posted by Michael Wonder on 31 Jul 2023
FDA grants fast track designation to IVS-3001, a CAR-T cell therapy in the treatment of renal cell carcinoma
31 July 2023 - Invectys is pleased to announce the US FDA has granted fast track designation to its revolutionary product, IVS-3001.
IVS-3001 is a cutting-edge CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumour-specific antigen known as HLA-G.
